Abstract
We argue that random testing (i.e., polling the fraction of infected people in the population) is central to managing the COVID-19 pandemic because it both measures the key variable controlled by restrictive measures, and anticipates the load on the healthcare system via the progression of the disease. Knowledge of random testing outcomes will therefore (i) significantly improve the predictability of the course of the pandemic, (ii) allow informed and optimized decisions on how to modify restrictive measures, with much shorter delay times than the present ones, and (iii) enable the real-time assessment of the efficiency of new means to reduce transmission rates (such as new tracing strategies based on the mobile telephone network, wearing face masks, etc.).
Frequent random testing for COVID-19 infections has the essential benefit of providing more reliable and refined data than are currently available, in both time and space. This is crucial to accompany and monitor the safe release of restrictive measures.
Here we show that independent of the total size of population with frequent interactions among its members, about 15’000 tests with randomly selected people per day suffice to obtain valuable data about the current number of infections and their evolution in time. In contrast to testing confined to particular subpopulations such as those displaying symptoms, this will allow close to real-time assessment of the quantitative effect of restrictive measures. With yet higher testing capacity, random testing further allows detection of geographical differences in spreading rates and thus the formulation of optimal strategies for a safe reboot of the economy. Most importantly, with daily random testing in place, a reboot could be attempted while the fraction of infected people is still an order of magnitude higher than the level required for a reboot without such polling.
These predictions are obtained from examining a feedback and control model of the pandemic where the feed-back is derived from random testing. In addition, we describe simulation strategies for decision support concerning testing, local quarantine regimes, and the safety of a reboot.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
GA acknowledges the support through the ERC HERO project under grant No. 810451.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data generated by the numerical simulations can be provided upon request to the authors.